Navigation Links
Actos Caused Bladder Cancer and Wrongful Death of New York Woman, Alleges Lawsuit Filed by Parker Waichman LLP
Date:7/9/2013

New York, New York (PRWEB) July 09, 2013

Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed a lawsuit alleging that Actos is to blame for the bladder cancer and subsequent wrongful death of a New York woman. The suit was filed on May 23, 2013, in the U.S. District Court for the Western District of Louisiana (Case No. 6:13-cv-1239). It is one of thousands of cases that have been filed as part of the multidistrict litigation (MDL) entitled In Re: Actos (pioglitazone) Products Liability Litigation (6:11-md-2299). Takeda Pharmaceuticals, America; Takeda Pharmaceuticals USA, Inc. f/k/a Takeda Pharmaceuticals North America, Inc.; Takeda Pharmaceutical Company Limited; and Eli Lilly and Company have been named as Defendants. Jerrold S. Parker, founding partner of Parker Waichman LLP, serves on the Plaintiffs’ Steering Committee in the litigation.

According to the Complaint, the Plaintiff’s Decedent started taking Actos in 2001. The Decedent was diagnosed with bladder cancer in December 2008 and subsequently died in June 2012, allegedly because of Actos’ side effects. The lawsuit alleges that the Decedent suffered from extensive pain and suffering and severe emotional distress as a result of using Actos. The drug also allegedly reduced the Decedent’s ability to enjoy life.

The U.S. Food and Drug Administration (FDA) has warned about the risks of taking Actos. In June 2011, the agency said that taking Actos for more than a year could significantly increase the risk of bladder cancer. The safety label on Actos was updated to address this risk.

Some research studies support the notion of a link between Actos and bladder cancer. The British Medical Journal published a study on May 31, 2012, that revealed Actos users were twice as likely to develop bladder cancer after two years. Then, on July 3, 2012, the Canadian Medical Association Journal reported that patients taking the medication were 22 percent more likely to get bladder cancer.

Parker Waichman LLP continues to offer free legal consultations to victims of Actos injuries, including bladder cancer, heart problems, and eye injuries. If you or a loved one were diagnosed with bladder cancer after taking Actos, please contact their office by visiting yourlawyer.com. Free case evaluations are also available by calling 1-800-LAW-INFO (1-800-529-4636).

Contact:
Parker Waichman LLP
Gary Falkowitz, Managing Attorney
(800) LAW-INFO
(800) 529-4636
http://www.yourlawyer.com

Read the full story at http://www.prweb.com/releases/actos-bladder-cancer/072013/prweb10912790.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Florida Man Develops Bladder Cancer as Result of Taking Actos, Alleges Lawsuit Filed by Parker Waichman LLP
2. Actos Lawsuits Move Forward, as Bernstein Liebhard LLP Reports on Recent Status Conference in Federal Actos Bladder Cancer Litigation
3. Actos Lawsuit News: Plaintiff Claims Actos Causes Bladder Cancer, Rottenstein Law Group LLP Reports
4. Lawsuit Alleging Actos Caused Arizona Man’s Bladder Cancer Filed by Parker Waichman LLP
5. Buckfire & Buckfire, P.C. Dangerous Drug Lawyers Now Accepting Michigan Actos Lawsuits
6. Actos Lawsuits: Bernstein Liebhard LLP Notes Upcoming Status Conference in Actos Bladder Cancer Litigation
7. Parker Waichman LLP Represents Pennsylvania Man in Lawsuit Alleging Actos Caused his Bladder Cancer
8. Actos Lawsuits: Bernstein Liebhard LLP Notes More Than 1,500 Cases Now Filed in Federal Litigation
9. Actos Lawsuits Move Forward, as Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Actos Bladder Cancer Litigation
10. Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation
11. Alleged Actos Bladder Cancer Lawsuits Update: $6.5 Million Verdict Overturned as Resource4thePeople Attorneys Continue to Accept Cases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... , ... Comfort Keepers® of San Diego, CA is excited to announce they ... to drive cancer patients to and from their cancer treatments. Comfort Keepers provides ... life and ongoing independence. Getting to and from medical treatments is one of ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its first-ever ... Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding work ... Practice and Pediatric Emergency Medicine Practice. , “With this award, we recognize ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital ... area economy by obtaining investment capital for emerging technology companies. SCP has ... have already resulted in more than a million dollars of capital investment for ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, ... stem (iPS) cells and other difficult to transfect cells, announces its launch of ... PluriQ™ G9™ Gene Editing System is a complete system for culturing and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... develops, markets and sells medical devices and wearable sleep ... a strategic cooperation agreement with Hongyuan Supply Chain Management ... on June 20, 2016, to develop Dehaier,s new Internet ... agreement, Dehaier will leverage Hongyuan Supply Chain,s sales platform ...
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
Breaking Medicine Technology: